CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Clinical trial NCT06834282 · RECRUITING

Trial details

NCT number: NCT06834282
Sponsor: CERo Therapeutics Holdings, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

AML Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2025-04-07
Primary completion: 2026-12-31
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.